Jiangxi Taijili Biopharmaceutical Technology

Jiangxi Taijili Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Nanchang, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on the Janus kinase (JAK) signaling pathway, targeting a range of autoimmune disorders and hematologic malignancies. Its lead candidate, TGL101, is a potent JAK inhibitor currently being evaluated in Phase 2 clinical trials for myelofibrosis and other inflammatory conditions. Taijili aims to leverage its proprietary drug discovery platform to develop next-generation inhibitors with improved selectivity and safety profiles. The firm is led by a team of experienced scientists with extensive backgrounds in global pharmaceutical R&D.